JP2009518024A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009518024A5 JP2009518024A5 JP2008543892A JP2008543892A JP2009518024A5 JP 2009518024 A5 JP2009518024 A5 JP 2009518024A5 JP 2008543892 A JP2008543892 A JP 2008543892A JP 2008543892 A JP2008543892 A JP 2008543892A JP 2009518024 A5 JP2009518024 A5 JP 2009518024A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- dom16
- egfr
- ligand
- binding specificity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003446 ligand Substances 0.000 claims 109
- 102000001301 EGF receptor Human genes 0.000 claims 97
- 108060006698 EGF receptor Proteins 0.000 claims 97
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 83
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 83
- 108060003951 Immunoglobulin Proteins 0.000 claims 77
- 102000018358 immunoglobulin Human genes 0.000 claims 77
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 74
- 102000004169 proteins and genes Human genes 0.000 claims 18
- 108090000623 proteins and genes Proteins 0.000 claims 18
- 125000003275 alpha amino acid group Chemical group 0.000 claims 16
- 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 claims 8
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 claims 8
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 claims 8
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims 8
- 239000000203 mixture Substances 0.000 claims 7
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims 7
- 102000006747 Transforming Growth Factor alpha Human genes 0.000 claims 6
- 101800004564 Transforming growth factor alpha Proteins 0.000 claims 6
- 102400001368 Epidermal growth factor Human genes 0.000 claims 5
- 101800003838 Epidermal growth factor Proteins 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 5
- 229940116977 epidermal growth factor Drugs 0.000 claims 5
- 102000039446 nucleic acids Human genes 0.000 claims 5
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- NMWKYTGJWUAZPZ-WWHBDHEGSA-N (4S)-4-[[(4R,7S,10S,16S,19S,25S,28S,31R)-31-[[(2S)-2-[[(1R,6R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,53S,56S,59S,62S,65S,68S,71S,76S,79S,85S)-47-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-4-oxobutanoyl]amino]-3-carboxypropanoyl]amino]-18-(4-aminobutyl)-27,68-bis(3-amino-3-oxopropyl)-36,71,76-tribenzyl-39-(3-carbamimidamidopropyl)-24-(2-carboxyethyl)-21,56-bis(carboxymethyl)-65,85-bis[(1R)-1-hydroxyethyl]-59-(hydroxymethyl)-62,79-bis(1H-imidazol-4-ylmethyl)-9-methyl-33-(2-methylpropyl)-8,11,17,20,23,26,29,32,35,38,41,48,54,57,60,63,66,69,72,74,77,80,83,86-tetracosaoxo-30-propan-2-yl-3,4,44,45-tetrathia-7,10,16,19,22,25,28,31,34,37,40,49,55,58,61,64,67,70,73,75,78,81,84,87-tetracosazatetracyclo[40.31.14.012,16.049,53]heptaoctacontane-6-carbonyl]amino]-3-methylbutanoyl]amino]-7-(3-carbamimidamidopropyl)-25-(hydroxymethyl)-19-[(4-hydroxyphenyl)methyl]-28-(1H-imidazol-4-ylmethyl)-10-methyl-6,9,12,15,18,21,24,27,30-nonaoxo-16-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29-nonazacyclodotriacontane-4-carbonyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-3-carboxy-1-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](Cc4ccccc4)NC3=O)[C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N3CCC[C@H]3C(=O)N[C@@H](C)C(=O)N2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2c[nH]cn2)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)C(C)C)C(=O)N[C@@H](Cc2c[nH]cn2)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1)C(=O)N[C@@H](C)C(O)=O NMWKYTGJWUAZPZ-WWHBDHEGSA-N 0.000 claims 4
- 102000007562 Serum Albumin Human genes 0.000 claims 4
- 108010071390 Serum Albumin Proteins 0.000 claims 4
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 4
- 230000002401 inhibitory effect Effects 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims 4
- 229960000397 bevacizumab Drugs 0.000 claims 3
- 229960005395 cetuximab Drugs 0.000 claims 3
- 238000012377 drug delivery Methods 0.000 claims 3
- 239000006199 nebulizer Substances 0.000 claims 3
- 229920001184 polypeptide Polymers 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 101000851181 Homo sapiens Epidermal growth factor receptor Proteins 0.000 claims 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 2
- 108010009583 Transforming Growth Factors Proteins 0.000 claims 2
- 102000009618 Transforming Growth Factors Human genes 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 102000045108 human EGFR Human genes 0.000 claims 2
- 238000001727 in vivo Methods 0.000 claims 2
- 238000001361 intraarterial administration Methods 0.000 claims 2
- 238000007918 intramuscular administration Methods 0.000 claims 2
- 238000007912 intraperitoneal administration Methods 0.000 claims 2
- 238000007913 intrathecal administration Methods 0.000 claims 2
- 238000001990 intravenous administration Methods 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000002685 pulmonary effect Effects 0.000 claims 2
- 238000011002 quantification Methods 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- 238000007920 subcutaneous administration Methods 0.000 claims 2
- 239000003053 toxin Substances 0.000 claims 2
- 231100000765 toxin Toxicity 0.000 claims 2
- 230000037317 transdermal delivery Effects 0.000 claims 2
- 101100279566 Arabidopsis thaliana EMB514 gene Proteins 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 101710112752 Cytotoxin Proteins 0.000 claims 1
- 208000034423 Delivery Diseases 0.000 claims 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims 1
- 102000008100 Human Serum Albumin Human genes 0.000 claims 1
- 108091006905 Human Serum Albumin Proteins 0.000 claims 1
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 108010001831 LDL receptors Proteins 0.000 claims 1
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 101100268514 Mus musculus Serpina1a gene Proteins 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 102000004338 Transferrin Human genes 0.000 claims 1
- 108090000901 Transferrin Proteins 0.000 claims 1
- 108010033576 Transferrin Receptors Proteins 0.000 claims 1
- 102100026144 Transferrin receptor protein 1 Human genes 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 230000000340 anti-metabolite Effects 0.000 claims 1
- 230000000692 anti-sense effect Effects 0.000 claims 1
- 229940100197 antimetabolite Drugs 0.000 claims 1
- 239000002256 antimetabolite Substances 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 239000002619 cytotoxin Substances 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- ZACLXWTWERGCLX-MDUHGFIHSA-N dom-1 Chemical compound O([C@@H]1C=C(C([C@@H](O)[C@@]11CO)=O)C)[C@@H]2[C@H](O)C[C@@]1(C)C2=C ZACLXWTWERGCLX-MDUHGFIHSA-N 0.000 claims 1
- 229940112141 dry powder inhaler Drugs 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 201000010175 gallbladder cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 125000003827 glycol group Chemical group 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 229940071648 metered dose inhaler Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 108010068617 neonatal Fc receptor Proteins 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000000906 photoactive agent Substances 0.000 claims 1
- 229920001515 polyalkylene glycol Polymers 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 150000003254 radicals Chemical class 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 239000012581 transferrin Substances 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 230000009677 vaginal delivery Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US74299205P | 2005-12-06 | 2005-12-06 | |
| US75835506P | 2006-01-11 | 2006-01-11 | |
| PCT/GB2006/004559 WO2007066106A1 (en) | 2005-12-06 | 2006-12-05 | Ligands that have binding specificity for egfr and/or vegf and methods of use therefor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009518024A JP2009518024A (ja) | 2009-05-07 |
| JP2009518024A5 true JP2009518024A5 (enExample) | 2009-12-24 |
Family
ID=37820653
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008543892A Pending JP2009518024A (ja) | 2005-12-06 | 2006-12-05 | Ｅｇｆｒおよび／またはｖｅｇｆに対して結合特異性を有するリガンドおよびその使用法 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20100056439A1 (enExample) |
| EP (1) | EP1966242A1 (enExample) |
| JP (1) | JP2009518024A (enExample) |
| KR (1) | KR20080077261A (enExample) |
| AU (1) | AU2006323412A1 (enExample) |
| BR (1) | BRPI0619463A2 (enExample) |
| CA (1) | CA2632417A1 (enExample) |
| CR (1) | CR10024A (enExample) |
| EA (1) | EA013878B1 (enExample) |
| MA (1) | MA30021B1 (enExample) |
| NO (1) | NO20082386L (enExample) |
| TW (1) | TW200804425A (enExample) |
| WO (1) | WO2007066106A1 (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9321832B2 (en) * | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
| US7696320B2 (en) | 2004-08-24 | 2010-04-13 | Domantis Limited | Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor |
| GB0621513D0 (en) * | 2006-10-30 | 2006-12-06 | Domantis Ltd | Novel polypeptides and uses thereof |
| GB0724331D0 (en) * | 2007-12-13 | 2008-01-23 | Domantis Ltd | Compositions for pulmonary delivery |
| JP6035009B2 (ja) | 2007-08-22 | 2016-11-30 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 活性化可能な結合ポリペプチドおよびその同定方法ならびに使用 |
| EP2615115A3 (en) * | 2007-11-30 | 2014-01-08 | Glaxo Group Limited | Antigen-binding constructs |
| US20100260853A1 (en) * | 2007-12-13 | 2010-10-14 | Amrik Basran | Compositions for pulmonary delivery |
| US8454960B2 (en) * | 2008-01-03 | 2013-06-04 | The Scripps Research Institute | Multispecific antibody targeting and multivalency through modular recognition domains |
| CN115043946A (zh) | 2008-01-03 | 2022-09-13 | 斯克里普斯研究院 | 通过模块识别结构域的抗体靶向 |
| AU2009231439A1 (en) * | 2008-03-31 | 2009-10-08 | Glaxo Group Limited | Drug fusions and conjugates |
| WO2009127691A1 (en) | 2008-04-17 | 2009-10-22 | Ablynx N.V. | Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same |
| WO2010033249A2 (en) * | 2008-09-22 | 2010-03-25 | Massachusetts Institute Of Technology | Compositions of and methods using ligand dimers |
| TW201019962A (en) * | 2008-10-21 | 2010-06-01 | Domantis Ltd | Ligands that have binding specificity for DC-SIGN |
| CN102224169A (zh) * | 2008-11-26 | 2011-10-19 | 葛兰素集团有限公司 | 多肽、抗体可变结构域和拮抗剂 |
| EP3543256A1 (en) | 2009-01-12 | 2019-09-25 | Cytomx Therapeutics Inc. | Modified antibody compositions, methods of making and using thereof |
| BRPI1008014A2 (pt) * | 2009-02-19 | 2016-10-04 | Glaxo Group Ltd | domínio variável simples, ligante multiespecífico, antagonistas de tnfr1, e de receptor de tnf-alfa, uso do agonista de tnfr, antagonista anti-tnfr1, polipeptídeo ou ligante multiespecífico, método para tratar e/ou prevenir uma condição ou doença, ácido nucleico, vetor, e, hospedeiro |
| EP2398494A4 (en) | 2009-02-23 | 2015-10-28 | Cytomx Therapeutics Inc | Proproteins and their methods of use |
| WO2010136483A2 (en) * | 2009-05-28 | 2010-12-02 | Glaxo Group Limited | Antigen-binding proteins |
| MX2012000765A (es) * | 2009-07-16 | 2012-02-13 | Glaxo Group Ltd | Dominios variables sencillos de union de albumina anti-suero mejorados. |
| CN102781959A (zh) | 2010-02-05 | 2012-11-14 | 埃博灵克斯股份有限公司 | 能够结合血清白蛋白的肽和包含所述肽的化合物、构建体和多肽 |
| US9029328B2 (en) | 2010-03-24 | 2015-05-12 | The Brigham And Women's Hospital, Inc. | Methods for cardioprotection and cardioregeneration with dimers of EGF family ligands |
| WO2012009705A1 (en) | 2010-07-15 | 2012-01-19 | Zyngenia, Inc. | Ang-2 binding complexes and uses thereof |
| WO2012022703A2 (en) * | 2010-08-20 | 2012-02-23 | Glaxo Group Limited | Improved anti-serum albumin binding variants |
| WO2012069557A1 (en) * | 2010-11-24 | 2012-05-31 | Glaxo Group Limited | Multispecific antigen binding proteins targeting hgf |
| DK2714738T3 (en) | 2011-05-24 | 2019-01-28 | Zyngenia Inc | MULTIVALENT AND MONOVALENT MULTISPECIFIC COMPLEXES AND THEIR APPLICATIONS |
| US20140255471A1 (en) | 2013-03-11 | 2014-09-11 | Wake Forest University Health Sciences | Method of treating brain tumors |
| MX2015013163A (es) | 2013-03-15 | 2016-04-04 | Zyngenia Inc | Complejos multiespecificos multivalente y monovalentes y sus usos. |
| WO2015044386A1 (en) * | 2013-09-26 | 2015-04-02 | Ablynx Nv | Bispecific nanobodies |
| CN114478753A (zh) | 2015-01-21 | 2022-05-13 | 英伊布里克斯公司 | 非免疫原性单结构域抗体 |
| EP3253790A4 (en) * | 2015-02-06 | 2018-07-25 | University of Maryland, Baltimore | Tetra-specific, octameric binding agents and antibodies against clostridium difficile toxin a and toxin b for treatment of c. difficile infection |
| PT3322734T (pt) | 2015-07-16 | 2020-11-30 | Inhibrx Inc | Proteínas de fusão de ligação a dr5 multivalentes e multispecíficas |
| KR101685532B1 (ko) * | 2016-04-26 | 2016-12-13 | 한국프라임제약주식회사 | 혈관내피성장인자 수용체 융합단백질 |
| CN111936516B (zh) * | 2018-03-19 | 2023-03-03 | 上海药明生物技术有限公司 | 新型抗egfr抗体多肽 |
| JP7698581B2 (ja) * | 2019-03-29 | 2025-06-25 | グリーン・クロス・コーポレイション | 抗メソテリン抗体、抗ｃｄ３抗体又は抗ｅｇｆｒ抗体を含む融合タンパク質、それを含む二重特異性又は三重特異性抗体、及びその使用 |
| WO2022047169A1 (en) * | 2020-08-28 | 2022-03-03 | Trustees Of Boston University | Engineered extracellular receptor constructs and uses thereof |
| CN115724968B (zh) * | 2021-08-27 | 2023-08-08 | 三优生物医药(上海)有限公司 | Vegf结合分子及其用途 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL181342B1 (pl) * | 1994-03-17 | 2001-07-31 | Merck Patent Gmbh | Jednolancuchowe anty-EGFR Fv i przeciwciala anty-EGFR, czasteczka DNA, sposoby wytwarzania jednolancuchowego przeciwciala anty-EGFR i przeciwciala anty-EGFR oraz kompozycja farmaceutyczna PL PL PL PL PL PL PL |
| PT957929E (pt) * | 1996-10-25 | 2006-06-30 | Gilead Sciences Inc | Complexos de ligandos de acido nucleico do factor de crescimento endotelial vascular |
| ES2273415T3 (es) * | 1997-04-07 | 2007-05-01 | Genentech, Inc. | Anticuerpos anti-vegf. |
| AU2002211658A1 (en) * | 2000-10-13 | 2002-04-22 | Uab Research Foundation | Human anti-epidermal growth factor receptor single-chain antibodies |
| RU2295537C2 (ru) * | 2000-10-20 | 2007-03-20 | Тугаи Сейяку Кабусики Кайся | Модифицированное агонистическое антитело |
| US7667004B2 (en) * | 2001-04-17 | 2010-02-23 | Abmaxis, Inc. | Humanized antibodies against vascular endothelial growth factor |
| US20060073141A1 (en) * | 2001-06-28 | 2006-04-06 | Domantis Limited | Compositions and methods for treating inflammatory disorders |
| US20050271663A1 (en) * | 2001-06-28 | 2005-12-08 | Domantis Limited | Compositions and methods for treating inflammatory disorders |
| DE60305919T2 (de) * | 2002-06-28 | 2007-01-18 | Domantis Limited, Cambridge | Dual-specifische liganden mit erhöhter halbwertszeit |
| EP1558650A2 (en) * | 2002-11-08 | 2005-08-03 | Ablynx N.V. | Camelidae antibodies against immunoglobulin e and use thereof for the treatment of allergic disorders |
| EP1578801A2 (en) * | 2002-12-27 | 2005-09-28 | Domantis Limited | Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand |
| CA2529819A1 (en) * | 2003-06-30 | 2004-09-23 | Domantis Limited | Pegylated single domain antibodies |
| US20050106667A1 (en) * | 2003-08-01 | 2005-05-19 | Genentech, Inc | Binding polypeptides with restricted diversity sequences |
| EP2251357A1 (en) * | 2003-11-07 | 2010-11-17 | Ablynx N.V. | Camelidae single domain antibodies VHH directed against epidermal growth factor receptor and uses therefor |
| US20090252681A1 (en) * | 2005-10-11 | 2009-10-08 | Ablynx N.V. | Nanobodies and Polypeptides Against EGFR and IGF-IR |
-
2006
- 2006-12-05 TW TW095145121A patent/TW200804425A/zh unknown
- 2006-12-05 WO PCT/GB2006/004559 patent/WO2007066106A1/en not_active Ceased
- 2006-12-05 EP EP06820440A patent/EP1966242A1/en not_active Withdrawn
- 2006-12-05 JP JP2008543892A patent/JP2009518024A/ja active Pending
- 2006-12-05 BR BRPI0619463-0A patent/BRPI0619463A2/pt not_active IP Right Cessation
- 2006-12-05 KR KR1020087016537A patent/KR20080077261A/ko not_active Ceased
- 2006-12-05 US US12/086,020 patent/US20100056439A1/en not_active Abandoned
- 2006-12-05 EA EA200801172A patent/EA013878B1/ru not_active IP Right Cessation
- 2006-12-05 AU AU2006323412A patent/AU2006323412A1/en not_active Abandoned
- 2006-12-05 CA CA002632417A patent/CA2632417A1/en not_active Abandoned
-
2008
- 2008-05-26 NO NO20082386A patent/NO20082386L/no unknown
- 2008-05-27 CR CR10024A patent/CR10024A/es not_active Application Discontinuation
- 2008-06-02 MA MA30990A patent/MA30021B1/fr unknown
-
2012
- 2012-10-26 US US13/644,414 patent/US20130041136A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009518024A5 (enExample) | ||
| EP1916001B1 (en) | Human antibodies specific to KDR and uses thereof | |
| US11186642B2 (en) | Development of masked therapeutic antibodies to limit off-target effects: application to anti-EGFR antibodies | |
| JP2009518025A5 (enExample) | ||
| US20110178279A1 (en) | Development of masked therapeutic antibodies to limit off-target effects: application to anti-egfr antibodies | |
| AU3475100A (en) | Antibodies specific to kdr and uses thereof | |
| WO2021042694A1 (zh) | 抗vegf单域抗体及其应用 | |
| CN114106190A (zh) | 一种抗vegf/pd-l1双特异性抗体及其用途 | |
| CN114539415B (zh) | 一种抗PD-L1/VEGF/TGF-β多特异性抗体及其用途 | |
| WO2015070210A1 (en) | Epha3 and multi-valent targeting of tumors | |
| WO2024012539A1 (zh) | 抗Nectin-4抗体及其应用 | |
| WO2023031644A1 (en) | Anti-fibroblast activation protein (fap) single domain antibodies and uses thereof | |
| CN117659194B (zh) | 靶向egfr的纳米抗体、药物偶联物及其用途 | |
| CN103172741A (zh) | 新型全人源抗体 | |
| CN115073593B (zh) | 新型冠状病毒抗体及其用途 | |
| US9580499B2 (en) | VEGFR2/Ang2 compounds | |
| WO2022228424A1 (zh) | 一种抗egfr/vegf双功能融合蛋白及其用途 | |
| CN110467676B (zh) | 特异性结合egfr的单克隆抗体及其抗癌用途 | |
| JP2024530856A (ja) | コイルドコイル融合タンパク質 | |
| WO2021244553A1 (zh) | 一种抗pd-l1和egfr的四价双特异性抗体 | |
| CN110563846B (zh) | 一种特异性结合egfr的单克隆抗体及其抗癌用途 | |
| US11952402B2 (en) | Fusion protein containing trail and IgG binding domain and the uses thereof | |
| WO2025032541A2 (en) | Anti-egfr nanobodies and nanobody constructs, and related products and methods | |
| CN116355099A (zh) | 重组抗人ox40和pd-l1双特异抗体及应用 | |
| HK1118229B (en) | Human antibodies specific to kdr and uses thereof |